prikaz prve stranice dokumenta Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
  Download
PDF 1.94 MB
Scientific paper - Original scientific paper
Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
Multiple Sclerosis and Related Disorders, 62 (2022); 103798. https://doi.org/10.1016/j.msard.2022.103798
Habek, Mario; Piskač, Dominik; Gabelić, Tereza; Barun, Barbara; Adamec, Ivan; Krbot Skorić, Magdalena

Cite this document

Habek, M., Piskač, D., Gabelić, T., Barun, B., Adamec, I. & Krbot Skorić, M. (2022). Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab. Multiple Sclerosis and Related Disorders, 62.. doi: 10.1016/j.msard.2022.103798

Habek, Mario, et al. "Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab." Multiple Sclerosis and Related Disorders, vol. 62, 2022. https://doi.org/10.1016/j.msard.2022.103798

Habek, Mario, Dominik Piskač, Tereza Gabelić, Barbara Barun, Ivan Adamec and Magdalena Krbot Skorić. "Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab." Multiple Sclerosis and Related Disorders 62 (2022). https://doi.org/10.1016/j.msard.2022.103798

Habek, M., et al. (2022) 'Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab', Multiple Sclerosis and Related Disorders, 62. doi: 10.1016/j.msard.2022.103798

Habek M, Piskač D, Gabelić T, Barun B, Adamec I, Krbot Skorić M. Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab. Multiple Sclerosis and Related Disorders [Internet]. 2022 June [cited 2024 April 11];62. doi: 10.1016/j.msard.2022.103798

M. Habek, D. Piskač, T. Gabelić, B. Barun, I. Adamec and M. Krbot Skorić, "Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab", Multiple Sclerosis and Related Disorders, vol. 62, June 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:571097. [Accessed: 11 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
AuthorMario Habek
AuthorDominik Piskač
AuthorTereza Gabelić
AuthorBarbara Barun
AuthorIvan Adamec
AuthorMagdalena Krbot Skorić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Objective: To determine the influence of immunoglobulins (Ig) level on the rate of infections in people with multiple sclerosis (pwMS) treated with ocrelizumab. ----- Methods: We enrolled 109 consecutive pwMS treated with ocrelizumab with a mean follow-up of 2.69±0.56 (1.36-4.27) years. We have retrospectively searched our electronic database and the following information was collected: age, sex, MS characteristics, number of ocrelizumab cycles, infections, duration of the infection, hospitalization due to infection, treatment of the infection, and COVID-19 characteristics. Ig levels were measured within 14 days before each ocrelizumab infusion. ----- Results: Number of pwMS with values of IgM and IgG below lower level of normal at baseline was 3 (2.8%) and 2 (2.8%), respectively; and before 6th cycle of ocrelizumab 5 (13.5%) and 5 (13.5%), respectively. Levels of IgM were steadily decreasing over time, while levels of IgG started to show statistically significant drop only after 5th cycle of ocrelizumab. 58.7% pwMS experienced infection during treatment, with a median number of infections per pwMS being 1, range 0-4. Female sex increased the risk of any infection (HR 2.561, 95%CI 1.382-4.774, p=0.003). Higher age and smaller drop in IgM before 3rd ocrelizumab cycle increased the risk for infection requiring hospitalization (HR 1.086, 95%CI 1.018-1.159, p=0.013 and HR 9.216, 95%CI 1.124-75.558, p=0.039, respectively). Longer disease duration increased the risk for COVID-19 (HR 1.075, 95%CI 1.002-1.154, p=0.045). ----- Conclusion: The present findings broaden limited real-world data on infection and COVID-19 risk in pwMS treated with ocrelizumab.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMultiple Sclerosis and Related Disorders
Numberingvol. 62, 103798
p-ISSN2211-0348
DOIhttps://doi.org/10.1016/j.msard.2022.103798
URN:NBNurn:nbn:hr:105:571097
Publication2022-06
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S2211034822003108
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-12-08 09:09:49